To assess the capability of each HDAC subtype in upregulating CD47 expression, we treated CRC cells with inhibitors for type I HDAC (entinostat), type IIa HDAC (TMP269), type IIb HDAC (ricolinostat), type III HDAC (nicotinamide), or type IV HDAC (SIS17). Here, CD47 is linked to colorectal carcinoma.